Cellectis Past Earnings Performance
Past criteria checks 0/6
Cellectis's earnings have been declining at an average annual rate of -0.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 5.6% per year.
Key information
-0.8%
Earnings growth rate
2.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -5.6% |
| Return on equity | -103.8% |
| Net Margin | -293.1% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cellectis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 25 | -72 | 14 | 84 |
| 30 Jun 23 | 25 | -77 | 16 | 88 |
| 31 Mar 23 | 25 | -91 | 16 | 92 |
| 31 Dec 22 | 26 | -91 | 17 | 98 |
| 30 Sep 22 | -5 | -63 | 11 | 97 |
| 30 Jun 22 | 4 | -78 | 16 | 108 |
| 31 Mar 22 | 14 | -99 | 20 | 113 |
| 31 Dec 21 | 39 | -86 | 23 | 118 |
| 30 Sep 21 | 68 | -129 | 40 | 120 |
| 30 Jun 21 | 67 | -121 | 41 | 106 |
| 31 Mar 21 | 59 | -113 | 41 | 97 |
| 31 Dec 20 | 60 | -37 | 23 | 77 |
| 30 Sep 20 | 73 | -79 | 41 | 94 |
| 30 Jun 20 | 73 | -66 | 41 | 96 |
| 31 Mar 20 | 71 | -67 | 44 | 98 |
| 31 Dec 19 | 23 | -102 | 43 | 92 |
| 30 Sep 19 | 20 | -88 | 45 | 83 |
| 30 Jun 19 | 11 | -95 | 45 | 80 |
| 31 Mar 19 | 17 | -69 | 45 | 73 |
| 31 Dec 18 | 21 | -79 | 47 | 77 |
| 30 Sep 18 | 25 | -83 | 50 | 75 |
| 30 Jun 18 | 31 | -86 | 50 | 77 |
| 31 Mar 18 | 31 | -105 | 49 | 77 |
| 31 Dec 17 | 34 | -99 | 45 | 79 |
| 30 Sep 17 | 40 | -86 | 44 | 79 |
| 30 Jun 17 | 45 | -74 | 42 | 74 |
| 31 Mar 17 | 57 | -56 | 42 | 78 |
| 31 Dec 16 | 56 | -67 | 43 | 78 |
| 30 Sep 16 | 76 | -45 | 40 | 76 |
| 30 Jun 16 | 74 | -45 | 38 | 79 |
| 31 Mar 16 | 65 | -64 | 37 | 73 |
| 31 Dec 15 | 63 | -23 | 30 | 58 |
| 30 Sep 15 | 39 | -28 | 25 | 44 |
| 30 Jun 15 | 37 | -10 | 21 | 30 |
| 31 Mar 15 | 33 | 12 | 17 | 19 |
| 31 Dec 14 | 32 | 3 | 16 | 17 |
| 30 Sep 14 | 28 | -8 | 16 | 19 |
| 30 Jun 14 | 24 | -21 | 18 | 22 |
| 31 Mar 14 | 21 | -29 | 21 | 23 |
| 31 Dec 13 | 18 | -36 | 24 | 25 |
| 30 Sep 13 | 15 | -33 | 23 | 22 |
| 30 Jun 13 | 18 | -31 | 25 | 21 |
Quality Earnings: ZVA is currently unprofitable.
Growing Profit Margin: ZVA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZVA is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare ZVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: ZVA has a negative Return on Equity (-103.81%), as it is currently unprofitable.